Clinical Research Directory

Inclusion Criteria: * Able to provide informed consent * European Cooperative Oncology Group performance status 0 to 2 * Medically fit for all protocol treatment and follow-up * Histologically confirmed adenocarcinoma of the prostate * Newly diagnosed any Tumor stage, any Nodal stage but with oligo metastases * No prior therapy for prostate cancer apart from androgen deprivation * Able to complete the necessary investigations prior to randomization (History and physical examination, PSA) * Able to complete the necessary investigations prior to start of Radiotherapy (Transrectal ultrasound-guided biopsy or equivalent, CT chest, abdomen \& pelvis or MRI abdomen and pelvis, and Bone scan) * Planned for long-term androgen deprivation therapy (greater than 9 months in duration) * Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study Exclusion Criteria: * High metastatic burden defined as 5 or more bone metastases or visceral metastases * Abnormal liver function * Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation Contraindications to brachytherapy including: * Medically unfit for anesthesia, * International Prostate Symptom Score (IPSS) greater than 20 * Poor urinary flow with peak flow rate less than10 mL per second or post-void residual greater than 25 per cent of voided volume (when uroflowmetry available) * Prostate volume greater than 60cc after maximal cytoreduction * Pubic arch interference * Transurethral resection of prostate (TURP) within 12 weeks of brachytherapy